Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.

Bibliographic Details
Main Author:	PLOS ONE Staff
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4546425?pdf=render

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
by: Alberto Ferreira, et al.
Published: (2015-01-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
by: Sam Razavi, et al.
Published: (2021-02-01)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis
by: Agashivala, N., et al.
Published: (2021)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
by: David R. Griffin, et al.
Published: (2014-01-01)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Ki Won Jin, et al.
Published: (2021-07-01)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019-07-01)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016-06-01)

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
by: Pallavi Tyagi, et al.
Published: (2018-06-01)

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
by: Juliana Wons, et al.
Published: (2017-01-01)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
by: Nudleman E, et al.
Published: (2017-02-01)

The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration
by: Attila Kovacs, et al.
Published: (2018-11-01)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
by: Christof Haensli, et al.
Published: (2021-06-01)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
by: Mohamed A. Hamid, et al.
Published: (2021-04-01)

Progress of Aflibercept of clinical application for neovascular age-related macular degeneration
by: Yun-Yan Zheng, et al.
Published: (2021-10-01)

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
by: Hisashi Matsubara, et al.
Published: (2016-04-01)

Short-Term Outcomes following “Switching” to Monthly Ranibizumab in Neovascular Age-Related Macular Degeneration Showing Insufficient Response to Bimonthly Aflibercept
by: Jong Suk Lee, et al.
Published: (2021-01-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
by: Matthews Jane P, et al.
Published: (2008-06-01)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
by: Koike N, et al.
Published: (2019-07-01)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
by: Erkan Unsal, et al.
Published: (2018-12-01)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
by: Thi Ha Chau Tran, et al.
Published: (2017-01-01)

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
by: Thomas M, et al.
Published: (2013-03-01)

Densitometric analysis of cornea in patients with neovascular age-related macular degeneration after intravitreal aflibercept loading dose
by: Cemile Ucgul Atilgan, et al.
Published: (2020-08-01)

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
by: Khanani AM
Published: (2015-07-01)

Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration
by: Beata Urban, et al.
Published: (2020-01-01)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
by: Thi Ha Chau Tran, et al.
Published: (2018-01-01)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2017-04-01)

Visual Findings in Neovascular Macular Degeneration Refractory to Bevacizumab after Intravitreal Aflibercept Therapy
by: Moazez, Carmel
Published: (2016)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
by: Dilan Yildiz, et al.
Published: (2021-06-01)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
by: Yi-Sheng Chang, et al.
Published: (2018-05-01)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
by: Tryfon Rotsos, et al.
Published: (2010-11-01)

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
by: Zhe-Li Liu, et al.
Published: (2013-04-01)

Long-term outcomes of Ranibizumab treatment in neovascular age-related macular degeneration
by: Burak Simsek, et al.
Published: (2018-02-01)

Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study
by: Joke Ruys, et al.
Published: (2020-09-01)

Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis
by: Gokcen Gokce, et al.

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
by: Tuncay Topal, et al.
Published: (2017-06-01)

Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study
by: Laurent Kodjikian, et al.
Published: (2020-10-01)

Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
by: Kanako Itagaki, et al.
Published: (2020-07-01)

Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.

Similar Items

Similar Items